Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
397 Results for "
Complement
" in MedChemExpress (MCE) Product Catalog:
Products (397)
397 Results for "Complement" in MCE Product Catalog:
Cat. No.: HY-200854
CAS No.: 2447007-60-3
Synonyms: LNP023 hydrochloride hydrate
Target:
Research Areas:
Iptacopan (LNP023) hydrochloride hydrate is an effective and orally-active highly selective factor B inhibitor with an IC50 value of 10 nM and KD of 7.9 nM. Iptacopan hydrochloride hydrate exerts a proximal effect in the complement cascade reaction, preventing the destruction (hemolysis) of red blood cells in PNH and the damage of renal cells in IgAN and C3G. Iptacopan hydrochloride hydrate can be used for the study of complement-mediated diseases, particularly paroxysmal nocturnal hemoglobinuria (PNH), primary immunoglobulin A nephropathy (IgAN), and complement 3 glomerulopathy (C3G) .
Cat. No.: HY-P991127
CAS No.: 2922766-89-8
Synonyms: DNTH103
Target:
Research Areas:
Cat. No.: HY-P72108
Purity: ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: C1QA; Complement Component 1, Q Subcomponent, A Chain; Complement C1q A Chain; Complement C1q Chain A; Complement C1q Subcomponent Subunit A; Complement Component C1q, A Chain; Complement Component 1, Q Subcomponent, Alpha Polypeptide; C1QD1
Species:
Mouse
Source:
E. coli
Cat. No.: HY-W727837
CAS No.: 847696-49-5
Target:
Research Areas:
Bisphenol S disulfate disodium has an inhibitory effect on complement (IC50 = 660 μM) .
Cat. No.: HY-127105B
CAS No.: 1644670-38-1
Synonyms: LNP023 TFA
Target:
Research Areas:
Iptacopan (LNP023) TFA is an effective and orally-active highly selective factor B inhibitor with an IC50 value of 10 nM and KD of 7.9 nM. Iptacopan TFA exerts a proximal effect in the complement cascade reaction, preventing the destruction (hemolysis) of red blood cells in PNH and the damage of renal cells in IgAN and C3G. Iptacopan TFA can be used for the study of complement-mediated diseases, particularly paroxysmal nocturnal hemoglobinuria (PNH), primary immunoglobulin A nephropathy (IgAN), and complement 3 glomerulopathy (C3G) .
Cat. No.: HY-P99050
CAS No.: 2049079-64-1
Synonyms: BIVV009; IPN-009; TNT009
Target:
Research Areas:
Cat. No.: HY-P700696
Purity: ≥ 90%, as determined by Bis-Tris PAGE.
Synonyms: C1S; Complement C1s Subcomponent; Complement C1s; C1 Esterase; Complement Component 1, S Subcomponent; Basic Proline-Rich Peptide IB-1; Complement Component 1 Subcomponent S; EDSPD2
Species:
Human
Source:
HEK293
Cat. No.: HY-P3252AS
Research Areas:
Cat. No.: HY-P991022
CAS No.: 2842046-67-5
Synonyms: NM8074
Target:
Research Areas:
Cat. No.: HY-P99638
CAS No.: 2456407-94-4
Synonyms: ALXN1720
Target:
Research Areas:
Gefurulimab (ALXN1720) is a high-affinity antibody inhibitor targeting complement protein C5, which can specifically bind to C5 and inhibit its cleavage into C5a and C5b. Gefurulimab can block the activation of the terminal complement pathway and reduce inflammatory damage. Gefurulimab can effectively reduce the formation of membrane attack complex (MAC) and has good pharmacokinetic properties. Gefurulimab can be used to study kidney and autoimmune diseases related to abnormal activation of the complement system, such as IgA nephropathy, lupus nephritis, and myasthenia gravis .
Cat. No.: HY-P706122
Purity: ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: C4B; Basic Complement C4; Complement C4B (Chido/Rodgers Blood Group); Complement C4B1a; CPAMD3; Complement C4-B; C4B1; C4B5; C4B3; Complement Component 4B (Chido/Rodgers Blood Group), Copy 2; CO4; Complement Protein C4B Frameshift Mutant; C4F; Chido Form
Species:
Human
Source:
E. coli
Cat. No.: HY-P705583
Purity: ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: C8G; Complement Component C8 Gamma Chain; Complement C8 Gamma Chain; C8C; Complement Component 8, Gamma Polypeptide
Species:
Mouse
Source:
E. coli
Cat. No.: HY-P72890
Purity: ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: CR2; Complement C3d Receptor; Complement C3d Receptor 2; EBV Receptor; C3DR; Complement Receptor; Complement Receptor Type 2; CD21 Antigen; CD21; CVID7; Complement Component (3d/Epstein Barr Virus) Receptor 2; SLEB9; Complement Component 3d Receptor 2; Cr
Species:
Human
Source:
HEK293
Cat. No.: HY-P77602
Purity: ≥ 95%, as determined by Bis-Tris PAGE.
Synonyms: CR2; Complement C3d Receptor; Complement C3d Receptor 2; EBV Receptor; C3DR; Complement Receptor; Complement Receptor Type 2; CD21 Antigen; CD21; CVID7; Complement Component (3d/Epstein Barr Virus) Receptor 2; SLEB9; Complement Component 3d Receptor 2; Cr
Species:
Mouse
Source:
HEK293
Cat. No.: HY-P75463A
Purity: ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: C1sa; C1s; C1s1; Complement C1s-A subcomponent light chain; Complement C1s-A subcomponent heavy chain; Complement component 1, S subcomponent 1; Complement component 1 subcomponent s-A; Complement C1s-A subcomponent; C1 esterase; EC:3.4.21.42; Complement
Species:
Mouse
Source:
HEK293
Cat. No.: HY-P990091
CAS No.: 2756228-76-7
Synonyms: SAR445088
Target:
Research Areas:
Riliprubart (SAR445088) is a selective anti-C1s humanized IgG4 monoclonal antibody with mutations that enhance its binding to the neonatal Fc receptor. Riliprubart blocks activation of the classical complement pathway, prevents the formation of the C3 convertase C4b2a, and inhibits complement-mediated hemolytic activity. Riliprubart can be used in research related to classical complement-mediated diseases, cold agglutinin disease, and chronic inflammatory demyelinating polyneuropathy. For the isotype control of Riliprubart, refer to Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .
Cat. No.: HY-P991954
Target:
Research Areas:
Cat. No.: HY-174913
CAS No.: 1644670-23-4
Target:
Research Areas:
Factor B-IN-5 is an orally active complement factor B (CFB) inhibitor. Factor B-IN-5 alleviates kidney damage in diabetes nephropathy by inhibiting the over activation of complement system and improving mitochondrial function. Factor B-IN-5 can improve renal tubulointerstitial inflammation and fibrosis. Factor B-IN-5 can be used for research on diabetic nephropathy .
Cat. No.: HY-178284
CAS No.: 3031666-94-8
Target:
Research Areas:
Factor B-IN-7 (Compound (I)) is a selective Factor B inhibitor. Factor B-IN-7 inhibits Factor B-C3b interaction to suppress complement hyperactivation. Factor B-IN-7 is promising for research of paroxysmal nocturnal hemoglobinuria (PNH), C3 glomerulopathy, and age-related macular degeneration (AMD) associated with complement-mediated diseases .
Cat. No.: HY-145720
CAS No.: 1639264-46-2
Synonyms: ALN-CC5
Research Areas:
Cemdisiran (ALN-CC5) is an N-acetylgalactosamine-conjugated RNAi agent and also a complement component C5 inhibitor. Cemdisiran targets C5 mRNA, cleaves C5 mRNA via the endogenous RNA interference pathway, and inhibits the production of C5 protein in the liver. Cemdisiran exerts a dose-dependent inhibitory effect on total C5 concentrations in cynomolgus monkeys. When used in combination with Pozelimab (HY-P99786) in cynomolgus monkeys, Cemdisiran achieves a more sustained and complete inhibitory effect on complement activity. Cemdisiran can be used in the research of paroxysmal nocturnal hemoglobinuria and other complement-mediated diseases .
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
